Weight-loss drug development has moved well past single-target GLP-1 drugs like semaglutide. Three of the most-discussed next-generation candidates, UBT251, retatrutide, and CagriSema, each take a different multi-receptor approach, and each is at a different point in development. None of the three is FDA-approved; all are investigational.
The Mechanisms, Compared
Retatrutide and UBT251 are both "triple agonists," designed to activate the GLP-1, GIP, and glucagon receptors simultaneously; the added glucagon activity is intended to boost energy expenditure on top of the appetite-suppressing effects GLP-1 and GIP provide. CagriSema takes a different approach entirely, pairing semaglutide (a GLP-1 agonist) with cagrilintide, an amylin receptor agonist, targeting appetite regulation through two separate hormone systems rather than three receptors on one molecule. Each mechanism is discussed in more depth in this site's dedicated guides to retatrutide and to cagrilintide and CagriSema.
Trial Stage and Sponsor
Retatrutide is furthest along: Eli Lilly has run it through its Phase 3 TRIUMPH program, with trial data reported in adults with obesity as well as in people with type 2 diabetes and cardiovascular disease, covered in this site's news coverage. CagriSema, developed by Novo Nordisk, has also reached Phase 3, but had a setback: in a head-to-head trial against Lilly's tirzepatide (marketed as Zepbound), CagriSema underperformed. UBT251, developed by United Biotechnology in partnership with Novo Nordisk, is earliest-stage of the three, with its most substantial data so far coming from a single Phase 2 trial conducted in China.
Weight Loss Results, Compared
Cross-trial comparisons like this one come with an important caveat: these are separate trials, in different populations, over different time periods, using different comparator groups, so the numbers aren't a true apples-to-apples comparison. With that caveat, reported results include: retatrutide's TRIUMPH-2 trial showing an average weight loss of up to 20.8% (about 49.6 lbs) at 80 weeks; CagriSema showing 23% weight loss at 84 weeks in its head-to-head trial, versus 25.5% for Zepbound in the same trial; and UBT251's highest dose showing 19.7% weight loss at just 24 weeks in its Phase 2 trial, a considerably shorter time frame than the other two.
What's Not Yet Known
Longer trials sometimes show diminishing returns compared with early data, and safety and tolerability over years of use, not just months, matters for a chronic weight-management drug. None of these three compounds has completed the full regulatory review process, and there's no guarantee any specific one will ultimately reach approval in its current form; drug candidates that look promising in Phase 2 sometimes underperform in larger, longer Phase 3 trials, and CagriSema's head-to-head result against Zepbound is itself an example of a next-generation candidate not automatically outperforming the drug it was designed to beat.
The Bottom Line
UBT251, retatrutide, and CagriSema represent three genuinely different strategies for improving on first-generation GLP-1 drugs, at three different stages of development, and none is available to patients outside a clinical trial today. Anyone following this space should expect the competitive picture to keep shifting as more Phase 3 data reads out, and should rely on currently FDA-approved medications, discussed with their own doctor, for actual treatment decisions.